Glepaglutide

Product Name: Glepaglutide

Form: Acetate salt

CAS No: 914009-86-2

Molar Mass: 4316.08

Chemical Formula: C197H325N53O55

Synonyms: ZP1848

Storage: Store at -20℃

Sequence: HGEGTFSSELATILDALAARDFIAWLIATKITDKKKKKK-NH2

Target: GLP-2R

Application:

Glepaglutide (CAS: 914009-86-2) is a novel peptide-based drug that functions as a glucagon-like peptide-2 (GLP-2) analog. GLP-2 is an intestinal hormone known for its role in promoting mucosal growth, enhancing nutrient absorption, and maintaining intestinal barrier function. Glepaglutide mimics the action of endogenous GLP-2 and is being developed for the treatment of short bowel syndrome (SBS), a condition characterized by inadequate intestinal absorption due to surgical resection, congenital defect, or disease. By stimulating intestinal growth and enhancing nutrient absorption, glepaglutide aims to improve intestinal function and reduce the dependence on parenteral nutrition in patients with SBS. In pharmaceutical research, glepaglutide represents a promising therapeutic option for addressing the underlying pathology of SBS and improving the quality of life for affected individuals. Clinical trials are ongoing to evaluate its safety, efficacy, and long-term effects in patients with SBS, with the goal of providing a much-needed treatment option for this challenging condition.

Current Research:

Glepaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes (T2D) and obesity. It is designed to provide sustained blood sugar control and weight reduction by mimicking the actions of GLP-1, a natural hormone that helps regulate insulin secretion, glucose metabolism, and appetite. Glepaglutide has shown promise due to its prolonged duration of action, which may offer benefits in patient compliance and management of metabolic disorders.

Mechanism of Action
Glepaglutide works by binding to the GLP-1 receptor, initiating a series of biological responses that include enhanced insulin secretion in response to meals, reduced glucagon release, and delayed gastric emptying. These actions help lower blood glucose levels and reduce appetite. Additionally, its long-acting formulation provides a sustained therapeutic effect, allowing for less frequent dosing compared to traditional GLP-1 receptor agonists. This can improve patient adherence and provide more stable glucose control over time.

Clinical Research and Efficacy
Clinical studies on glepaglutide have demonstrated its efficacy in reducing HbA1c levels and promoting weight loss in individuals with T2D and obesity. In Phase 2 clinical trials, glepaglutide showed a significant reduction in HbA1c, with some participants experiencing weight loss of up to 6%. The long-acting formulation of glepaglutide also contributed to improved patient satisfaction due to the reduced frequency of injections. Adverse events were generally mild, with gastrointestinal symptoms being the most commonly reported. Ongoing studies continue to evaluate the long-term safety and efficacy of glepaglutide in diverse patient populations.

Regulatory Status and Potential Applications
Glepaglutide is currently undergoing clinical trials for the treatment of T2D and obesity. It is expected to be a key player in the management of metabolic disorders due to its potent effects on both blood glucose and weight. Additionally, its potential to improve patient adherence through less frequent dosing makes it an attractive option in chronic disease management. Researchers are also investigating its use in other conditions related to metabolic dysfunction, such as non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease.

Conclusion
Glepaglutide is a promising GLP-1 receptor agonist that offers sustained blood glucose control and weight management with the advantage of less frequent dosing. Ongoing clinical trials and research into its long-term effects underscore its potential to become an essential treatment option for T2D, obesity, and related metabolic conditions. As the drug progresses through clinical development, its innovative formulation could significantly impact the way metabolic disorders are managed.

Reference:

Skarbaliene, J., Mathiesen, J. M., Larsen, B. D., Thorkildsen, C., & Petersen, Y. M. (2023). Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats. BMC gastroenterology, 23(1), 79.

Agersnap, M. A., Sonne, K., Knudsen, K. M., Knudsen, C. B., & Berner-Hansen, M. (2022). Pharmacokinetics of glepaglutide, a long-acting glucagon-like peptide-2 analogue: a study in healthy subjects. Clinical Drug Investigation, 42(12), 1093-1100.